Clinical efficacy and safety of different antiplatelet drugs in acute coronary syndrome patients receiving percutaneous coronary intervention with low clopidogrel response
BAI Yan-yan
SHI Jun
LIU Cheng
LIU Xin-bing
XU Qi-tan
FENG Liu-liu
Abstract：Objective To investigate the efficacy and safety of two different antiplatelet agents in patients with low clopidogrel response after percutaneous coronary intervention (PCI) in acute coronary syndromes (ACS). Methods 120 ACS patients in ShiDong hospital with ADP (Adenosine diphosphate) inhibition rate less than 30%by thrombelastography from Dec.2014 to Feb.2016 were enrolled (63 males and 57 females with an average age of 68.03±4.93 years) and randomly divided into two groups: 60 patients in observation group received aspirin (100mg daily) and ticagrelor (90 mg twice daily); and 60 patients in control group received aspirin (100 mg daily), clopidogrel (75 mg daily) and cilostazol (50 mg twice daily). Thrombelastography was performed one week after treatment, and the platelet ADP inhibition rate was evaluated in both groups. The patients were followed up for an average of 6.7 months. The adverse events such as bleeding, dyspnea, stomach discomfort, cardiac death, acute myocardial infarction, stent thrombosis and re-intervention or coronary artery bypass grafting were observed.Results There was no significant difference between the two groups in age, sex, comorbidity, drug combination and ADP inhibition rate (P<0.05). Thrombolysis after one week of treatment showed that the inhibition rate of ADP was significantly higher than that before treatment (P<0.01). The inhibitory rate of ADP was (56.78±8.42) %, which was higher than that of the control group (43.28±6.24) % (P<0.05). No serious adverse cardiac events and major bleeding events occurred in either group (P>0.05). There were two patients in the observation group who had a reduction in the amount of mucosal haemorrhage, and one in the control group discontinued aspirin because of gastric ulcer. Conclusion Two treatments were effective and safety in ACS patients receiving PCI with low clopidogrel response. The treatment effect of Tigreilol was better.
Keywords：Acute coronary syndromeTicagrelorCilostazolLow clopidogrel responseThrombelastography
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 1491-1493 )